IONS logo

IONS Ionis Pharmaceuticals Inc

$44.32
$0.32
(0.73%)
Overnight
26

Bearish Sentiment

How do you feel about IONS?

Loading...
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
Zacks
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Zacks
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Zacks
Ionis announces positive interim data from partner Roches Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen...
Business Wire
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Stocktwits
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
Zacks
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Key PointsIonis has six commercial therapies, mostly focused on rare diseases...
Nasdaq News: Markets
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.
Zacks
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks